Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 4000 shares trading hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Performance
The company has a market cap of C$1.33 million, a price-to-earnings ratio of -1.50 and a beta of 0.05. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a 50 day moving average price of C$0.02 and a two-hundred day moving average price of C$0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last issued its quarterly earnings data on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.16 million during the quarter. Analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- The Risks of Owning Bonds
- 3 Momentum Trades for October With Ample Upside Ahead
- 3 Monster Growth Stocks to Buy Now
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
